Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Target Price of $7.50

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $7.67.

GANX has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Finally, BTIG Research reiterated a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a report on Monday.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in Gain Therapeutics in the 2nd quarter valued at about $1,283,000. Potomac Capital Management Inc. purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $3,252,000. Apollon Wealth Management LLC increased its holdings in shares of Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after buying an additional 6,675 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter worth approximately $277,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter worth approximately $35,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Trading Down 1.2%

GANX opened at $1.67 on Friday. The firm has a market capitalization of $72.88 million, a price-to-earnings ratio of -3.34 and a beta of 0.19. The company’s 50 day simple moving average is $1.83 and its two-hundred day simple moving average is $1.83. Gain Therapeutics has a 1-year low of $1.53 and a 1-year high of $4.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. Analysts expect that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.